Biomerica IncNASDAQ:BMRANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.3895
- TODAY'S CHANGE (%)0.0674 (20.9252%)
- Bid / Lots0.3901/ 10
- Ask / Lots0.4037/ 30
- Open / Previous Close0.3920 / 0.3221
- Day Range
- 52 Week Range
- Volume25,051,794
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BMRA |
|---|---|---|
| 09:32 ET | 205145 | 0.4043 |
| 09:33 ET | 179715 | 0.39355 |
| 09:35 ET | 265697 | 0.417 |
| 09:37 ET | 412475 | 0.416099 |
| 09:39 ET | 156562 | 0.4078 |
| 09:42 ET | 135640 | 0.4201 |
| 09:44 ET | 1288814 | 0.44 |
| 09:46 ET | 494754 | 0.4187 |
| 09:48 ET | 250075 | 0.4239 |
| 09:50 ET | 388402 | 0.42074 |
| 09:51 ET | 523431 | 0.43 |
| 09:53 ET | 225902 | 0.420008 |
| 09:55 ET | 148954 | 0.4125 |
| 09:57 ET | 177863 | 0.4183 |
| 10:00 ET | 190782 | 0.411455 |
| 10:02 ET | 107947 | 0.415699 |
| 10:04 ET | 149109 | 0.4218 |
| 10:06 ET | 205448 | 0.4086 |
| 10:08 ET | 95124 | 0.4129 |
| 10:09 ET | 132758 | 0.4057 |
| 10:11 ET | 272747 | 0.3973 |
| 10:13 ET | 99633 | 0.3928 |
| 10:15 ET | 118385 | 0.3944 |
| 10:18 ET | 76420 | 0.395899 |
| 10:20 ET | 71851 | 0.392299 |
| 10:22 ET | 43600 | 0.39 |
| 10:24 ET | 182170 | 0.3701 |
| 10:26 ET | 142868 | 0.372 |
| 10:27 ET | 43722 | 0.375 |
| 10:29 ET | 59489 | 0.3765 |
| 10:31 ET | 37598 | 0.376 |
| 10:33 ET | 32161 | 0.383307 |
| 10:36 ET | 36511 | 0.3898 |
| 10:38 ET | 11689 | 0.3865 |
| 10:40 ET | 109305 | 0.393 |
| 10:42 ET | 39024 | 0.4 |
| 10:44 ET | 23873 | 0.397 |
| 10:45 ET | 41594 | 0.3958 |
| 10:47 ET | 16464 | 0.392601 |
| 10:49 ET | 37453 | 0.3997 |
| 10:51 ET | 129147 | 0.405713 |
| 10:54 ET | 27448 | 0.407399 |
| 10:56 ET | 22103 | 0.4018 |
| 10:58 ET | 21812 | 0.3953 |
| 11:00 ET | 15232 | 0.39735 |
| 11:02 ET | 57695 | 0.4 |
| 11:03 ET | 26328 | 0.4035 |
| 11:05 ET | 40675 | 0.4064 |
| 11:07 ET | 25433 | 0.4097 |
| 11:09 ET | 111200 | 0.4218 |
| 11:12 ET | 55654 | 0.42 |
| 11:14 ET | 21766 | 0.414 |
| 11:16 ET | 37229 | 0.4116 |
| 11:18 ET | 58236 | 0.4188 |
| 11:20 ET | 52531 | 0.42205 |
| 11:21 ET | 54038 | 0.4246 |
| 11:23 ET | 43720 | 0.4201 |
| 11:25 ET | 86686 | 0.4301 |
| 11:27 ET | 78130 | 0.4317 |
| 11:30 ET | 52370 | 0.4199 |
| 11:32 ET | 91948 | 0.4203 |
| 11:34 ET | 57473 | 0.4156 |
| 11:36 ET | 20224 | 0.413 |
| 11:38 ET | 160656 | 0.4144 |
| 11:39 ET | 41850 | 0.4076 |
| 11:41 ET | 14726 | 0.4125 |
| 11:43 ET | 6991 | 0.4115 |
| 11:45 ET | 13859 | 0.4135 |
| 11:48 ET | 10505 | 0.4142 |
| 11:50 ET | 51682 | 0.4137 |
| 11:52 ET | 25776 | 0.40765 |
| 11:54 ET | 19357 | 0.406 |
| 11:56 ET | 9512 | 0.4246 |
| 11:57 ET | 1894 | 0.4061 |
| 11:59 ET | 36152 | 0.4116 |
| 12:01 ET | 6098 | 0.4116 |
| 12:03 ET | 47461 | 0.4021 |
| 12:06 ET | 57747 | 0.40051 |
| 12:08 ET | 5050 | 0.4065 |
| 12:10 ET | 63667 | 0.396962 |
| 12:12 ET | 30329 | 0.39665 |
| 12:14 ET | 51660 | 0.3962 |
| 12:15 ET | 24239 | 0.4 |
| 12:17 ET | 50548 | 0.407227 |
| 12:19 ET | 35016 | 0.4 |
| 12:21 ET | 76404 | 0.3994 |
| 12:24 ET | 35113 | 0.4124 |
| 12:26 ET | 45285 | 0.41 |
| 12:28 ET | 19855 | 0.4113 |
| 12:30 ET | 24277 | 0.4002 |
| 12:32 ET | 107102 | 0.4 |
| 12:33 ET | 9301 | 0.3974 |
| 12:35 ET | 470 | 0.4073 |
| 12:37 ET | 28617 | 0.40395 |
| 12:39 ET | 10138 | 0.419 |
| 12:42 ET | 8413 | 0.419 |
| 12:44 ET | 11070 | 0.4 |
| 12:46 ET | 8128 | 0.402006 |
| 12:48 ET | 21818 | 0.400961 |
| 12:50 ET | 33549 | 0.395 |
| 12:51 ET | 23149 | 0.396001 |
| 12:53 ET | 27492 | 0.395801 |
| 12:55 ET | 66150 | 0.3954 |
| 12:57 ET | 72931 | 0.388001 |
| 01:00 ET | 154633 | 0.3895 |
Nov 21, 2024
Biomerica Secures Three Key International Patents for inFoods(R) Technology to Address GERD, Crohn's Disease, and Ulcerative Colitis, from 8:19AM ET on Thursday Nov 21, 2024 by Dow Jones
8:19AM ET on Thursday Nov 21, 2024 by Dow Jones
Nov 7, 2024
Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements, from 9:09AM ET on Thursday Nov 07, 2024 by Dow Jones
9:09AM ET on Thursday Nov 07, 2024 by Dow Jones
Oct 30, 2024
Biomerica Announces Direct-to-Consumer Availability of inFoods(R) IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain, from 8:19AM ET on Wednesday Oct 30, 2024 by Dow Jones
8:19AM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Biomerica Inc | 5.4M | -1.1x | --- |
Encision Inc | 4.9M | -7.0x | --- |
SINTX Technologies Inc | 5.3M | 0.0x | --- |
NAYA Biosciences Inc | 4.6M | -0.3x | --- |
NeuroMetrix Inc | 8.8M | -0.9x | --- |
Predictive Oncology Inc | 5.2M | -0.3x | --- |
Company Information
Biomerica, Inc. is a biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are utilized in the analysis of blood, urine, nasal, or fecal samples for the diagnosis of various diseases, food intolerances, and other medical conditions. Its range of medical diagnostic products is sold primarily in two markets: clinical laboratories and point-of-care settings, including physicians’ offices and over-the-counter sales. It is focused on research and development efforts and is its patented diagnostic-guided therapy (DGT) product, developed on the in Foods technology platform. Its inFoods IBS product, uses a simple blood test to identify patient-specific foods that, when eliminated, may alleviate IBS symptoms such as pain, bloating, diarrhea, cramping, and constipation. Its hp+detect, a new diagnostic test for detecting Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract.
Contact Information
- Headquarters
- 17571 VON KARMAN AVENUEIRVINE, CA, United States 92614
- Phone
- 949-379-2875
- Fax
- 949-553-1231
Executives
- Chief Executive Officer, Director
- Zackary Irani
- Executive Vice Chairperson of the Board and Corporate Secretary
- Allen Barbieri
- Chief Financial Officer
- Gary Lu
- Independent Director
- Catherine Coste
- Independent Director
- Jane Emerson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.4M |
|---|---|
Revenue (TTM) | $5.5M |
Shares Outstanding | 16.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.16 |
EPS | $-0.37 |
Book Value | $0.39 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | 1.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -118.10% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
